Insmed Contingent payments for Business Acquisition increased by 350.2% to $54.87M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 350.2%, from $12.19M to $54.87M.
An increase indicates the successful achievement of acquisition-related milestones, potentially signaling integration progress or product development success.
The value of equity issued to satisfy contingent consideration obligations arising from past business acquisitions. Thes...
Common in biopharma and tech companies that grow through M&A and milestone-based earnouts.
other_stock_issued_during_period_value_contingent_paymen_5e3f7f| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $12.19M | $12.19M | $12.19M | $12.19M | $54.87M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +350.2% |
| YoY Change | — | — | — | — | +350.2% |